K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.

K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.

Item
http://www.wikidata.org/entity/Q38742728
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsALK: a tyrosine kinase target for cancer therapy.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Role and targeting of anaplastic lymphoma kinase in cancer.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancerFrequency of actionable alterations in epidermal growth factor receptor wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR)
P2860

K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.

Item
http://www.wikidata.org/entity/Q38742728
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
K-RAS mutations indicating pri ...... and review of the literature.
@en
type
label
K-RAS mutations indicating pri ...... and review of the literature.
@en
prefLabel
K-RAS mutations indicating pri ...... and review of the literature.
@en
P1433
P1476
P2093
P304
P31
P356
P478
P50
P577
P698
P921
P356
P1433
P1476
K-RAS mutations indicating pri ...... and review of the literature.
@en
P2093
P304
P31
P356
10.1016/J.LUNGCAN.2016.01.002
P478
P50
P577
P698
P921